Endogenous Markers of Tumor Hypoxia: Predictors of Clinical Radiation Resistance?

Strahlentherapie und Onkologie

Volumn 179, Issue 12, 2003, Pages 801-811

  Vordermark, Dirk ^a,b   Brown, J Martin ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hypoxia markers; Radiation resistance; Radiotherapy; Tumor hypoxia

Indexed keywords

CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PIMONIDAZOLE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; LUNG CANCER; OXYGENATION; PROGNOSIS; RADIOSENSITIVITY; REOXYGENATION; REVIEW; SOFT TISSUE SARCOMA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASES; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; FORECASTING; GLUCOSE TRANSPORTER TYPE 1; HEAD AND NECK NEOPLASMS; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MONOSACCHARIDE TRANSPORT PROTEINS; NEOPLASMS; OXYGEN; PROGNOSIS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TRIAZINES; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 0344667645     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-003-1150-9     Document Type: Review

References (82)

1. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61:2911-6.
2. Airley R, Loncaster J, Davidson S, et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 2001;7:928-34.
3. Bartosova M, Parkkila S, Pohlodek K, et al. Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J Pathol 2002;197.314-21.
4. Beasley NJ, Leek R, Alam T, et al. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 2002;62: 2493-7.
5. Beasley NJ, Wykoff CC, Watson PH, et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 2001;61:5262-7.
6. Becker A, Kuhnt T, Liedtke H, et al. Oxygen measurements in head and neck cancers during hyperbaric oxygenation. Strahlenther Onkol 2002;178: 105-8.
7. Becker A, Stadler P, Krause U, et al. Association between elevated serum VEGF and polarographically measured tumor hypoxia in head and neck carcinomas. Strahlenther Onkol 2001;177:182-8.
8. Behrooz A, Ismail-Beigi F. Stimulation of glucose transport by hypoxia: signals and mechanisms. News Physiol Sci 1999;14:105-10.
9. Birner P, Gatterbauer B, Oberhuber G, et al. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 2001;92:165-71.
10. Birner P, Schindl M, Obermair A, et al. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693-6.
11. Bimer P, Schindl M, Obermair A, et al. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001;7:1661-8.
12. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-3.
13. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000;6:157-62.
14. Chapman JD, Engelhardt EL, Stobbe CC, et al. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998;46:229-37.
15. Chen C, Pore N, Behrooz A, et al. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 2001;276:9519-25.
16. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995;36:1625-32.
17. Cooper R, Sarioglu S, Sökmen S, et al. Glucose transporter 1 (GLUT-1): a potential marker of tumour hypoxia and prognosis in rectal cancer? Radiother Oncol 2002;64: Suppl 1:S19.abstract.
18. Dachs GU, Patterson AV, Firth JD, et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997;3:515-20.
19. Dunst J, Becker A, Lautenschlager C, et al. Anemia and elevated systemic levels of vascular endothelial growht factor (VEGF). Strahlenther Onkol 2002;178:436-41.
20. Dunst J, Stadler P, Becker A, et al. Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers. Strahtenther Onkol 2001;177:469-73.
21. Fyles A, Milosevic M, Hedley D, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002;20:680-7.
22. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001; 85:881-90.
23. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001; 61:7992-8.
24. Gross MW, Karbach U, Groebe K, et al. Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int J Cancer 1995;61:567-73.
25. Haber RS, Rathan W, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 1998;83: 34-40.
26. Hall EJ. Radiobiology for the radiologist, 3rd edn. Philadelphia: Lippincott, 1988.
27. Haugland HK, Vukovic V, Pintilie M, et al. Expression of hypoxia-inducible factor-1alpha in cervical carcinomas: correlation with tumor oxygenation. Int J Radiat Oncol Biol Phys 2002;53:854-61.
28. Hermans R. Estimation of tumour oxygenation levels with dynamic contrast-enhanced magnetic resonance imaging. Radiother Oncol 2000;57: 1-3.
29. Höckel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15.
30. Hui EP, Chan AT, Pezzella F, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular Endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002;8:2595-604.
31. Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001;158:905-19.
32. Jansen HL, Haustermans KM, Sprong D, et al. HIF-1alpha, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys 2002;54:1537-49.
33. Jewell UR, Kvietikova I, Scheid A, et al. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J 2001;15:1312-4.
34. 2 tension. Am J Physiol 1996;271:C1172-80.
35. Kaanders JH, Pop LA, Marres HA, et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 52:769-78.
36. Kaanders JH, Wijffels KI, Marres HA, et al. ARCON: how to select patients for this new treatment strategy? Radiother Oncol 2002;64:Suppl 1:S103. abstract.
37. Kaanders JH, Wijffels KI, Marres HA, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066-74.
38. Kaluz S, Kaluzova M, Chrastina A, et al. Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 Alpha stabilization: a role for phosphatidylinositol 3′-kinase. Cancer Res 2002;62:4469-77.
39. Kivelä AJ, Parkkila S, Saarnio J, et al. Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours. Histochem Cell Biol 2000;114:197-204.
40. 2-measurements in the treatment of carcinoma of the uterine cervix. Radiother Oncol 1999;53:99-104.
41. Koukourakis MI, Giatromanotaki A, Sivridis E, et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001;7:3399-403.
42. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible factor (HIF 1A and HIF 2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 53:1192-202.
43. Koukourakis MI, Giatromanolaki A, Skarlatos J, et al. Hypoxia inducible factor (HIF-1α and HIF-2α) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 2001;61:1830-2.
44. Lal A, Peters H, St Croix B, et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 2001;93:1337-43.
45. Lando D, Peet DJ, Whelan DA, et al. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 2002;295:858-61.
46. Le QT, Kovacs MS, Dorie MJ, et al. Comparison of the comet assay and the oxygen Microelectrode to measure tumor oxygenation in head and neck cancer patients. Int J Radiat Oncol Biol Phys 2003;56:375-83.
47. Liu SC, Minton NP, Giaccia AJ, et al. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther 2002;9:291-6.
48. Loncaster JA, Harris AL, Davidson SE, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001;61:6394-9.
49. Mellanen P, Minn H, Grenman R, et al. Expression of glucose transporters in head-and-neck tumors. Int J Cancer 1994;56:622-9.
50. Nordsmark N, Alsner J, Keller J, et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001;84:1070-5.
51. Nordsmark M, Loncaster J, Chou SC, et al. Invasive oxygen measurements and pimonidazoLe labeling in human cervix carcinoma. Int J Radiat Oncol Biol Phys 2001;49:581-6.
52. Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000;57: 39-43.
53. Olive PL, Aquino-Parsons C, MacPhail SH, et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 2001; 61:8924-9.
54. Patterson AV, Williams KJ, Cowen RL, et al. Oxygen-sensitive enzyme-pro-drug gene therapy for the eradication of radiation resistant solid tumours. Gene Ther 2002;9:946-54.
55. Pedersen MW, Holm S, Lund EL, et al. Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia 2001;3:80-7.
56. Popple R, Ove R, Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys 2002;54:921-7.
57. Raleigh JA, Calkins-Adams DP, Rinker LH, et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 1998;58:3765-8.
58. Raleigh JA, Chou SC, Arteel GE, et al. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 1999;151:580-9.
59. 2 histography in patients with advanced head and neck cancer. Strahlenther Onkol 2001;177:462-8.
60. Schindl M, Schoppmann SF, Samonigg H, et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002;8:1831-7.
61. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physial 2000;88:1474-80.
62. Semenza GL. HIF-1 and mechanisms of oxygen sensing. Curr Opin Cell Biol 2001;13:167-71.
63. Shibata T, Giaccia AJ, Brown JM. Hypoxia-inducible regulation of a pro-drug-activating enzyme for tumor-specific gene therapy. Neoplasia 2002; 4:40-8.
64. Sivridis E, Giatromanolaki A, Gatter KC, et al. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 2002;95: 1055-63.
65. Sondergaard KL, Hilton DA, Penney M, et al. Expression of hypoxia-inducible factor 1alpha in tumours of patients with glioblastoma. Neuropathol Appl Neurobiol 2002;28:210-7.
66. Stroka DM, Burkhardt T, Desbaillets I, et al. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 2001;15:2445-53.
67. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000;157: 411-21.
68. Vaupel P, Thews O, Mayer A, et al. Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther Onkol 2002; 178:727-31.
69. Volm M, Koomagi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res 2000;20: 1527-33.
70. Vordermark D. Expression of hypoxia-inducible factor-1alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis [Letter]. Cancer 2002;94:2317-8.
71. Vordermark D, Brown JM. Evaluation of hypoxia-inducible factor-1α (HIF-1α) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: in-vitro and xenograft studies. Int J Radiat Oncol Biol Phys 2003; 56:1184-93.
72. Vordermark D, Menke DR, Brown JM. Similar radiation sensitivities of acutely and chronically hypoxic cells in HT 1080 fibrosarcoma xenografts. Radiat Res 2003;159:94-101.
73. Vordermark D, Shibata T, Brown JM. Green fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophore formation. Neoplasia 2001;3:527-34.
74. Vukovic V, Haugland HK, Nicklee T, et al. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res 2001;61:7394-8.
75. West CM, Cooper RA, Loncaster JA, et al. Tumor vascularity: a histological measure of angiogenesis and hypoxia. Cancer Res 2001;61:2907-10.
76. Wiesener MS, Munchenhagen PM, Berger I, et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001;61:5215-22.
77. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075-83.
78. Younes M, Brown RW, Stephenson M, et al. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997;80:1046-51.
79. Younes M, Lechago LV, Somoano JR, et al. Wide expression of the human erythrocyte glucose transporter Glut 1 in human cancers. Cancer Res 1996; 56:1164-7.
80. Zagzag D, Zhong H, Scalzitti JM, et al. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000;88:2606-18.
81. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
82. Zhong H, Mabjeesh N, Willard M, et al. Nuclear expression of hypoxia-inducible factor 1alpha protein is heterogeneous in human malignant cells under normoxic conditions. Cancer Lett 2002;181:233-8.